Early Phase 1 N=5 RHD Genotype Matched Red Cells for Anti-D
Sickle Cell Disease · Anti-D Antibodies
Primary: Anti-D Recurrence — 0; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 RhD+ Blood Transfusion to Asian-type DEL Recipients
Blood Transfusion · Rhesus Isoimmunisation Due to Anti-D · Blood Group Antigen Abnormality
Primary: Occurrence of Alloanti-D Immunization in Asian-type DEL Recipients Transfused With RhD+ RBCs — 42; 12 Participants — p=< 0.001
Phase 2 N=62 Pharmacokinetics and Safety of Roledumab in RhD-negative Pregnant Women Carrying an RhD-positive Foetus
Rh Disease
Primary: CL/F : Apparent Clearance — 0.0106 L/h
Phase 4 N=92 Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
Hyperbilirubinemia · Erythroblastosis, Fetal
Primary: Need of Exchange Transfusion — 6; 7 participants — p=0.765
Phase 2 N=11 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
Phase 2 N=21 RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
Upper Respiratory Tract Infection · Lower Respiratory Tract Infection
Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change
Phase 2 N=276 Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Area Under the Concentration-Time Curve From Time 0 to 336 Hours (AUC0-336) Post First Dose — 49000; 49000; 51400 ug*h/ml
N/A N=39 ABCA3 Gene and RDS in Late Preterm and Term Infants
Respiratory Distress Syndrome, Newborn
Primary: Mortality — 5; 3; 5 Participants
Phase 2 N=509 A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women
Respiratory Syncytial Virus Infections
Primary: Percentage of Subjects With Any Solicited Local Adverse Event (AEs) [Primary Study] — 5.9; 5; 5.8; 5.9 Percentage of participants
N/A N=377 Age of Red Blood Cells in Premature Infants Study (ARIPI)
Premature Birth
Primary: 1. Composite Outcome of Necrotizing Enterocolitis, Intraventricular Hemorrhage, Bronchopulmonary Dysplasia and Retinopathy of Prematurity at 30 and 90-days. 2. Mortality…
Phase 2 N=18 Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)
Phase 3 N=140 A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
Rheumatoid Arthritis
Primary: Number of Subjects With Positive Anti-Drug Antibodies (ADA) on Day 1 — 3; 1 Participants
N/A N=25 Cord Blood Transfusion In Preterm Neonates (CB-TrIP)
Premature Infant Disease · Transfusion Related Complication · Fetal Hemoglobin
Primary: Median Percentage of HbF at 32 Weeks of Post Menstrual Age — 93.2; 90.8; 58.0; 69.0 percentage of total Hb — p=<0.0001
Phase 2 N=6 Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
DIRA
Primary: Number of Subjects Who Maintained Inflammatory Remission With Rilonacept — 6 Participants
Phase 2 N=1,153 A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
Respiratory Tract Infection
Primary: Percentage of Maternal Participants With Prespecified Local Reactions by Maximum Severity Within 7 Days After Vaccination — 3.5; 2.6; 5.2; 0.9 Percentage of participants
Phase 3 N=14,727 A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
Respiratory Tract Infection
Primary: Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)…
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
Phase 4 N=19 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Multiple Sclerosis
Primary: Incidence of Infusion Related Reactions With Rapid Infusion Will be Reported — 0; 0 infusion reactions
N/A N=15 The Effect of Rituximab on the Development of Anti-Donor Antibodies
Renal Transplant Rejection
Primary: Change in Biopsy Cell Densities From Baseline to Follow-up — -164; -122.5; -129.4; 30.4 cells/mm^3 — p=0.25
Phase 3 N=10 Rituximab in Rheumatoid Arthritis Lung Disease
Rheumatoid Arthritis · Interstitial Pneumonia
Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants
Phase 1 N=32 Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants
Phase 2 N=19 A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
Antiphospholipid Syndrome
Primary: Number of Participants Experiencing Serious and Non Serious Adverse Events — 19 Participants
Phase 2 N=419 Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
Respiratory Syncytial Virus Infections
Primary: Percentage of Maternal Subjects With Any Solicited Administration Site Events — 57.1; 52; 15.2; 1.4 Percentage of maternal subjects
N/A N=84 Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities
Respiratory Distress Syndrome
Primary: Respiratory Distress Syndrome — 52; 3 participants
Phase 2 N=121 IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Retinopathy of Prematurity (ROP)
Primary: Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population — 14; 24; 4; 4 participants — p=0.0642
Phase 2 N=30 Rituximab in IgG4-RD: A Phase 1-2 Trial
Retroperitoneal Fibrosis · Autoimmune Pancreatitis · Sialadenitis
Primary: IgG4-RD RI Score at Baseline and Six Months After Rituxan Treatment — 11; 1 units on a scale
Phase 4 N=384 Safety of RIV4 Versus IIV4 in Pregnant Women
Safety · Adverse Event Following Immunisation · Birth Outcomes
Primary: Number of Pregnant Women Vaccinated With RIV4 Versus IIV4 With Adverse Birth Outcomes — 17; 21 Participants — p=<0.0001
N/A N=265 Rheos® Pivotal Trial
Hypertension
Primary: Percent of Patients With a 10mmHg or Greater Reduction in Office Cuff Systolic Blood Pressure — 54.1; 46.4 percentage of participants
Phase 2 N=6 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs
Sickle Cell Disease · Thalassemia · Diamond-Blackfan Anemia
Primary: Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT) — 3 Participants
Phase 2 N=74 Preventive Approach to Congenital Heart Block With Hydroxychloroquine
Congenital Heart Block · Neonatal Lupus · Autoantibody-Associated Heart Block
Primary: Recurrence of Advanced Heart Block — 5 Participants